To include your compound in the COVID-19 Resource Center, submit it here.

BAY 43-9006: Phase I

Final data from 4 Phase I trials in 118 patients with advanced malignancies who received single-agent BAY 43-9006

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE